A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
第一作者:
Dan,Lu
第一单位:
Department of Clinical Pharmacology, Genentech, Inc., 1 DNA Way, MS 463A, South San Francisco, CA, 94080, USA.
作者:
主题词
抗肿瘤药(Antineoplastic Agents);剂量效应关系, 药物(Dose-Response Relationship, Drug);药物批准(Drug Approval);人类(Humans);最大耐受剂量(Maximum Tolerated Dose);分子靶向治疗(Molecular Targeted Therapy);肿瘤(Neoplasms);产品监测, 售后(Product Surveillance, Postmarketing);美国(United States);美国食品和药物管理局(United States Food and Drug Administration)
DOI
10.1007/s00280-015-2931-4
PMID
26811176
发布时间
2018-11-13
- 浏览3
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文